Clinical Trial Update: Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating a combination of sorafenib and everolimus in relapsed or refractory lymphoma and multiple myeloma with results posted after completio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Everolimus (everolimus)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Mayo Clinic | Conditions: Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-07-07